Brief: Oncolytics Biotech Says Co Expects To Initiate First Phase 3 Study for Pelareorep In Pancreatic Cancer In 2024
04/01/2024 12:05
Jan 4 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® RECAPS 2023 ACCOMPLISHMENTS, PROVIDES
OUTLOOK FOR 2024
* ONCOLYTICS BIOTECH INC - LOOKING AHEAD TO 2024, WE EXPECT
TO
INITIATE FIRST PHASE 3 STUDY FOR PELAREOREP IN PANCREATIC CANCER
* ONCOLYTICS BIOTECH: $40 MILLION CASH BALANCE AS OF SEPT
30,
GRANT FUNDING FROM PANCAN PROVIDES US WITH OVER 12 MONTHS OF
RUNWAY TO SUPPORT OPERATIONS
Source text for Eikon: ID:nCNWGfWXwa
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer